Faron Pharmaceuticals Oy (LSE:FARN) enters the autumn with the strongest Balance Sheet in its recent history and a single, high-stakes question hanging over it: can its lead antibody, bexmarilimab, prove itself in a randomised trial (LSE:FARN)? The Turku-based cancer immunotherapy developer reported on 26 August 2026 that cash had risen to €32.0m at 30 June 2026, following a €40.1m gross rights issue that was one of Finland's largest biotech financings.

That money matters because in March the FY2025 accounts warned that funds would last only until the second quarter of 2026, a going-concern uncertainty the rights issue has since removed. With a placebo-controlled Phase 2b study, BEXERA, due to start in the second half of this year, the coming months will set the tone for Faron's story on the London Stock Exchange's AIM market.

Half-year results: losses narrow as cash more than doubles

Faron's interim report for the six months to 30 June 2026, published on 26 August 2026, showed an operating loss of €11.1m, slightly better than the €11.8m recorded in the first half of 2025. Research and Development spending edged up to €7.6m from €7.1m, while general and administrative costs fell to €3.5m from €4.7m. Financial income of €3.0m, up from €0.6m, helped cut the loss before tax to €8.5m from €19.3m a year earlier, and the basic loss per share improved to €0.06 from €0.18.

There was no revenue, as expected for a clinical-stage biotech. Cash and cash equivalents stood at €32.0m against €13.5m a year earlier and €12.3m at the end of 2025. Borrowings totalled €17.8m, leaving net cash of roughly €14.2m and restoring shareholders' Equity to a positive €11.6m from a negative €19.0m at 31 December 2025.

Chief executive Dr Juho Jalkanen said the company had "successfully navigated a demanding period with determination and hard work", and set out the priorities for the rest of the year plainly: "initiate BEXERA, continue generating evidence from our IIT portfolio, and translate this into further value creation." As usual, Faron gave no short-term financial outlook.

What Faron does

Faron is a Finnish clinical-stage biopharmaceutical company whose lead asset, bexmarilimab, is an antibody targeting Clever-1, a receptor on macrophages. It aims to reprogramme immunosuppressive myeloid cells so the immune system can attack tumours, a different approach from the BCL-2 and CD47 pathways pursued by rivals.

The main programme is in higher-risk myelodysplastic syndrome (HR-MDS), a bone-marrow cancer with poor outcomes, where bexmarilimab is combined with the standard chemotherapy azacitidine. The antibody holds Orphan Drug designations from the European Medicines Agency and the US FDA for HR-MDS, and a positive end-of-Phase 2 FDA meeting in 2025 confirmed its development pathway.

Beyond MDS, the antibody is being tested through investigator-initiated trials in soft-tissue sarcoma (BEXAR), checkpoint-refractory melanoma and lung cancer (BLAZE) and residual-disease acute myeloid leukaemia after transplant (BEAM). Faron has no marketed products; its value rests on clinical data, partnering deals and eventual approval. Its shares trade as depositary interests on AIM and as ordinary shares on Nasdaq First North in Helsinki.

Financial reset: from going-concern warning to €40m rights issue

The FY2025 financial statements released on 4 March 2026 showed an operating loss of €19.0m and a loss for the year of about €27.2m, with cash of just €12.3m and borrowings of €24.5m at 31 December 2025. The directors said existing cash would fund activities only until Q2 2026.

On 10 March 2026 Faron published terms for a rights issue of up to 80,158,126 new shares at €0.50 each, on a 9-for-13 basis and at a 7.54% discount to the theoretical ex-rights price. The €40m offering was fully covered by subscription commitments of €4.71m, cornerstone commitments of €7.05m, including the Blood Cancer United Therapy Acceleration Program, and subscription guarantees of €28.32m. Nil-paid rights were briefly suspended on AIM on 30 March 2026 pending an announcement, and the remaining offer shares were registered on 14 April 2026. Gross proceeds were €40.1m with issue costs of €7.2m, according to the interim report.

Faron's Debt consists of convertible bonds issued to Heights Capital Management in 2025, in tranches of €15m and €10m due in April and December 2028. Amortisation can be settled in shares: on 3 August 2026 the company issued 3,657,321 shares at €0.4316 to cover €1.58m of repayments, lifting the registered share count to 227,881,315, of which 21,342,679 are held in treasury.

What could drive the stock next

The central catalyst is BEXERA, the randomised, placebo-controlled Phase 2b trial in frontline HR-MDS due to start in the second half of 2026 (LSE:FARN). It aims to enrol 90 patients across up to 35 sites in the US, Europe and the UK and to select a Phase 3 dose. Parexel was engaged as contract research organisation in April 2026, so a first-patient-dosed announcement is the next visible milestone.

Data from the existing BEXMAB Phase 1/2 study keep coming. On 27 July 2026 Faron reported first overall-survival data from 21 treatment-naive HR-MDS patients: median survival had not been reached in TP53 wild-type and monoallelic-mutated patients after 14.9 months of follow-up, while patients with biallelic TP53 mutations reached a median of 8.8 months. Chief medical officer Dr Petri Bono said the results "further support potential in frontline TP53 wild-type and mutated HR-MDS patients". Detailed data are promised at a scientific meeting later in 2026, and readouts from the investigator-led solid-tumour trials could broaden the story. The May 2026 election of biotech dealmaker Dr George Golumbeski to the board hints at partnering ambitions.

Risks investors should watch

Faron remains loss-making with no revenue, and the €32.0m cash pile will be consumed by a 90-patient randomised trial and up to five investigator-led studies. Further equity raises before any Phase 3 are plausible, and the convertible bonds add €25m of principal due in 2028 plus steady dilution through share-settled amortisation at market-linked prices.

Clinical risk is acute: single-arm Phase 1/2 data in a small cohort may not translate into a placebo-controlled setting, and the biallelic TP53 subgroup showed no clear survival benefit over historical comparators. Competition in HR-MDS is intense. Disclosure practice also warrants attention: on 5 June 2026 Nasdaq Helsinki's disciplinary committee fined Faron €30,000 for 2024 breaches of First North rules, requiring changes to how it times announcements across its two markets. Liquidity is split between London and Helsinki, and euro reporting introduces currency effects for sterling-based holders.

Outlook

Faron has bought itself time and credibility. The going-concern cloud has lifted, costs outside the laboratory are falling, and the clinical plan has regulatory endorsement. The next 12 months hinge on whether BEXERA starts on schedule and enrols briskly, whether maturing BEXMAB data hold up, and whether the investigator-led trials attract a partner. Watch for the first BEXERA patient, the promised scientific presentation later in 2026, further convertible amortisation announcements and, in early 2027, the FY2026 results for evidence of how far the rights-issue cash stretches.